Female Infertility Market is expected to reach US$ 28.6 Bn in 2030 with a growth rate of 5.7%.

The female infertility market involves products and services used to treat the inability to get pregnant or carry a pregnancy to term in women. Key drivers of market growth include the rising prevalence of infertility due to lifestyle changes, the trend of delayed pregnancies, government initiatives to make fertility treatments more accessible, and advancements in assisted reproductive technologies such as IVF and fertility drugs.

Recent developments like the integration of artificial intelligence and big data to improve IVF outcomes, use of microfluidics for better sperm sorting, and mitochondrial replacement therapy to avoid mitochondrial diseases are expanding the range of treatment options for female infertility patients. Growth opportunities lie in improving IVF success rates, male infertility treatment, fertility preservation services, and tapping emerging economies. However, high treatment costs, low insurance coverage, risks of ART procedures, and regulatory barriers remain key challenges.

The female infertility market is segmented by product type, procedures, end-user, and region. Key products in the market include equipment like incubators and IVF media & consumables which see repeat purchases. Major procedures comprise IVF, IUI, ICSI, fertility drugs, and genetic testing. Fertility clinics, hospitals, and cryobanks are the main end-users. Geographically, North America accounted for the largest share of over 38% of the global market in 2023.

Drivers:

• Rising median age of first-time mothers and delayed pregnancies, especially in developed countries, is increasing infertility rates. According to CDC, average age at first birth in the US rose from 21.4 years in 1970 to 26.3 years in 2018.
• Government initiatives like IVF insurance mandates in the US, NHS-funded IVF cycles in the UK, and subsidized programs in Japan are improving accessibility and affordability of infertility treatments.

Trends:

• Use of advanced technologies like artificial intelligence, big data, and automation to improve outcomes of IVF and fertility treatments.
• Fertility tourism is rising as patients travel to cheaper overseas destinations like Spain, Czech Republic, Thailand, and India for infertility treatments.

Opportunity:

• Emerging economies like China, India, Malaysia with growing middle-class populations offer significant growth opportunities for female infertility treatment.

Key Report Insights:

• North America accounted for over 38% market share in 2022, driven by high awareness, new product launches and favorable government policies. Major players include CooperSurgical, Vitrolife, and IVFtech. (50 words)
• Europe accounted for 28.7% market share in 2022, aided by initiatives like state-funded IVF cycles in the UK. Key players are Genea Biomedx, Kitazato, Thermo Fisher Scientific. (44 words)

Leading companies in the market are CooperSurgical, Vitrolife, Genea Biomedx, Thermo Fisher Scientific, Cook Medical, Esco Micro, Rocket Medical, IVFtech, and FUJIFILM Irvine Scientific. Most have strategic partnerships and acquisitions to expand services.

Female Infertility Market Segmentation:

• By Product & Services
  • Equipment
  • Media & Consumables
  • Services
• By Procedure
  • Assisted Reproductive Technology (ART)
  • Diagnostic Tests
• By End User
  • Fertility Clinics
  • Hospitals and Research Laboratories
  • Cryobanks
• By Region
  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • U.K.
    • Spain
    • France
    • Italy
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Argentina
    • Mexico
    • Rest of Latin America
  • Middle East & Africa
    • GCC Countries
    • Israel
    • South Africa
    • North Africa
    • Central Africa
    • Rest of the Middle East

Definition:

“The female infertility market involves products and services used for treating inability to get pregnant in women. It comprises of fertility drugs, IVF, IUI, ICSI, diagnosis tests, cryopreservation, and fertility surgery used by patients unable to conceive naturally.”